Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation

Hematology Am Soc Hematol Educ Program. 2010:2010:310-3. doi: 10.1182/asheducation-2010.1.310.

Abstract

A 64 year-old man with a history of multiple myeloma presents with new back pain. He has a history of International Staging System stage 1, IgG kappa multiple myeloma with normal cytogenetics which was diagnosed 4 years ago when he presented with a pathological fracture of the left humerus. He was initially managed with mechanical stabilization and 4 cycles of bortezomib-dexamethasone, as well as 2 years of bisphosphanates. Following induction therapy he achieved a very good partial response (VGPR). He subsequently received high-dose melphalan and autologous stem cell transplantation (auto-SCT) and achieved a complete reponse (CR) post-transplant. He did not receive maintenance therapy and had been lost-to follow-up for about a year. He now presents 5 years after initial diagnosis with back pain and is noted to have a new lytic lesion with a compression fracture at T8. A serum protein electrophoresis demonstrates reappearance of his original monoclonal protein. After appropriate stabilization he comes to you to discuss additional treatment options.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / therapeutic use*
  • Dose-Response Relationship, Drug
  • Evidence-Based Medicine*
  • Humans
  • Multiple Myeloma / drug therapy*
  • Recurrence
  • Stem Cell Transplantation*
  • Transplantation, Autologous

Substances

  • Antineoplastic Agents